Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Developments

Exscientia launches AWS AI-powered platform to advance drug discovery

Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...

July 10, 2024

Developments

Unicycive announces positive topline results from pivotal clinical trial in hyperphosphatemia

Unicycive Therapeutics (NASDAQ:UNCY) announced positive initial results from the patient reported outcome survey conducted during its pivotal clinical trial of oxylanthanum carbonate (OLC) in patients with...

July 10, 2024

Developments

Mainz Biomed submits application for FDA breakthrough device designation for CRC product

Mainz Biomed (NASDAQ:MYNZ) announced that it has submitted an application to the FDA requesting breakthrough device designation for its non-invasive, next-generation colorectal cancer (CRC) screening test, which...

July 9, 2024

Developments

ABVC announces joint effort with AiBtl for new clinical study on depression in cancer patients using AI

ABVC BioPharma (NASDAQ:ABVC) announced plans for a new clinical study in collaboration with AiBtl BioPharma on depression in cancer patients by integrating AI-driven solutions. The new study follows successful Phase II...

July 9, 2024

Developments

Defence announces receipt of NOL for Phase I trial of anti-cancer molecule

Defence Therapeutics (CSE:DTC; OTCQB:DTCFF; FSE:DTC) announced that it has received a “no objection letter” (NOL) from Health Canada authorizing the company to proceed with a Phase I trial of intratumoral administration...

July 8, 2024

Developments

CellProthera and BioCardia announce successful results from collaborative Phase II trial

Closely-held CellProthera, in collaboration with BioCardia (NASDAQ:BCDA), announced success from a collaborative Phase II trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI). The companies plan...

July 8, 2024

Developments

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Lucid Diagnostics (NASDAQ:LUCD) announced positive results from its clinical validation study of EsoGuard Esophageal DNA test on samples collected from patients with Barrett’s Esophagus (BE) and esophageal...

July 5, 2024

Developments

CureVac unveils restructuring plan to intensify focus on mRNA projects

CureVac (NASDAQ:CVAC) has announced a restructuring plan aimed at increasing its focus on high-value messenger RNA (mRNA) initiatives, with a particular emphasis on oncology and unmet medical needs. The company will...

July 5, 2024

Developments

PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia

Closely-held PharmaJet announced that its Tropis Intradermal (ID) Needle-free System was selected by WHO for use in a house-to-house immunization campaign targeting more than 170,000 children, age four to 59 months, in...

June 27, 2024

Developments

Lyell announces promising clinical data in TNBC

Lyell Immunopharma (Nasdaq:LYELL) has reported initial clinical and translational data from its Phase 1 trial of LYL797, a first-generation reprogrammed ROR1 CAR T cell product candidate enhanced with proprietary anti...

June 26, 2024

Developments

ANEW reports European patent for novel gene sequence and delivery systems in neurodegenerative disease

ANEW Medical (NASDAQ:WENA) has been granted and issued a patent from the European Patent Office (EPO) for the patent application covering the company’s secreted Klotho gene sequence and gene delivery system, intended...

June 26, 2024

Developments

Entrada reports positive data from Phase 1 DMD trial

Entrada Therapeutics (NASDAQ:TRDA) has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular...

June 24, 2024

Developments

SOPHiA GENETICS expands oncology portfolio with new RAM application

SOPHiA GENETICS (NASDAQ:SOPH) has announced its new residual acute myeloid (RAM) application, SOPHiA DDM RAM Solution, supporting measurable residual disease (MRD) testing to help monitor cancer and outpace relapse. The...

June 24, 2024

Developments

Former Hepion CEO sues over departure; cites bad faith dealings with investor

Former Hepion Pharmaceuticals (NASDAQ:HEPA) CEO, Robert Foster, PharmD, PhD, is suing the company and its Board members for illegal termination of his employment, breach of contract, and breach of the covenant of good...

June 13, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Developments

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health...

June 3, 2024

Developments

Verve Therapeutics appoints Troy Lister as CSO

Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity. Currently, Dr. Lister serves as...

June 3, 2024

Developments

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

Closely-held Lucy Therapeutics (LucyTX) raised $12.5 million in additional funding to further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target...

May 29, 2024

Subscribe